| pubmed-article:16889636 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C2741652 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C1956094 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C0006968 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C0949665 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C1521941 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C0033080 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C1261552 | lld:lifeskim |
| pubmed-article:16889636 | lifeskim:mentions | umls-concept:C1511545 | lld:lifeskim |
| pubmed-article:16889636 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16889636 | pubmed:dateCreated | 2007-1-18 | lld:pubmed |
| pubmed-article:16889636 | pubmed:abstractText | Antibiotic misuse is associated with emergence of resistance and high expenditures. Fluoroquinolones (FQ) and carbapenems (CP) are drugs with considerable potential of resistance development and its disseminated use is a concern. We undertook a prospective clinical audit to evaluate prescriptions of FQ and CP in a multistep process. Each prescription was unfolded in the following steps: indication for antimicrobial therapy; adequacy of initial prescription, dosage and route; previous cultures; and parenteral-oral transition. There was no antibiotics indication in 8.9% of FQ and 1.5% of CP group (p = 0.07). In CP 25.8% of initial schemes were inappropriate (21% in FQ). Lack of switch to oral therapy comprised 25% of monthly costs of FQ. Inadequacy in initial choice accounted for 13.6% of CP expenses. We concluded that, in spite of infection control restrictive policies, inappropriateness of antibiotic usage is worrisome. Clinical audit in a multistep approach may identify possible flaws in this process. | lld:pubmed |
| pubmed-article:16889636 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16889636 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16889636 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16889636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16889636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16889636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16889636 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16889636 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16889636 | pubmed:issn | 1368-5031 | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:SchroederGG | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:JacobiDD | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:RibeiroR ARA | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:PiretM CMC | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:GreterS-ESE | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:SeligmanB G... | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:MachadoA R... | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:KuchenbeckerR... | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:Dos SantosR... | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:CasaliF CFC | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:GuzattoFF | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:MoraisV DVD | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:KüplichN MNM | lld:pubmed |
| pubmed-article:16889636 | pubmed:author | pubmed-author:KonkewiczL... | lld:pubmed |
| pubmed-article:16889636 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16889636 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:16889636 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16889636 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16889636 | pubmed:pagination | 147-52 | lld:pubmed |
| pubmed-article:16889636 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:meshHeading | pubmed-meshheading:16889636... | lld:pubmed |
| pubmed-article:16889636 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:16889636 | pubmed:articleTitle | Critical steps in fluoroquinolones and carbapenems prescriptions: results from a prospective clinical audit. | lld:pubmed |
| pubmed-article:16889636 | pubmed:affiliation | Hospital Infection Control Committee, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil. seligman@via-rs.net | lld:pubmed |
| pubmed-article:16889636 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16889636 | pubmed:publicationType | Review | lld:pubmed |
